Clinical and cytogenetic characteristics CEBPAwt compared with CEBPAbi, CEBPAsmbZIP and CEBPAsmTAD mutant patients
| . | CEBPAwt n = 4468 . | CEBPAsmTAD n = 60 . | CEBPAsmbZIP n = 49 . | CEBPAbi n = 131 . | P (adj.) . |
|---|---|---|---|---|---|
| Age, y, median (IQR) | 57 (46-67) | 63 (55-69) | 50 (39-57) | 46 (38-59) | <.001 |
| Sex, n (%) | |||||
| Female | 2170 (49) | 32 (53) | 16 (33) | 70 (53) | .26 |
| Male | 2298 (51) | 28 (47) | 33 (67) | 61 (47) | |
| AML type, n (%) | |||||
| de novo | 3510 (78) | 50 (84) | 47 (96) | 122 (93) | .001 |
| sAML | 630 (14) | 8 (13) | 2(4) | 4 (3) | |
| tAML | 328 (7) | 2 (3) | — | 5 (4) | |
| Laboratory, median (IQR) | |||||
| BM blasts, % | 60 (38-80) | 60 (43.3-72.8) | 65.3 (43.9-80) | 64 (50-87) | .823 |
| CD34-positivity, % | 16 (2-47) | 19.2 (3.8-65) | 45 (19.5-68) | 55.6 (32.9-77) | <.001 |
| WBC, ×109/L | 11.7 (3-45.7) | 13.2 (3.3-51.2) | 35.7 (11.5-93) | 23.7 (9.3-64.7) | <.001 |
| LDH, U/L | 412.9 (272-727) | 412 (291-569) | 491 (344-941) | 445 (292-679) | .99 |
| FAB, n (%) | |||||
| M0 | 223 (5) | — | 1 (2) | — | <.001 |
| M1/M2 | 2040 (46) | 40 (67) | 39 (80) | 101 (77) | |
| M4-M7 | 1535 (34) | 15 (25) | 8 (16) | 19 (15) | |
| Unknown | 670 (15) | 5 (8) | 1 (2) | 10 (8) | |
| Cytogenetics, n (%) | |||||
| Normal karyotype | 1923 (43) | 37 (62) | 34 (72) | 102 (78) | <.001 |
| Aberrant karyotype | 2359 (53) | 23 (38) | 15 (28) | 29 (22) | |
| Unknown | 186 (4) | — | — | — | |
| Favorable risk (MRC) | 353 (8) | 1 (2) | 1 (2) | — | <.001 |
| Intermediate risk (MRC) | 2928 (68) | 54 (90) | 43 (92) | 119 (98) | |
| Adverse risk (MRC) | 1001 (23) | 5 (8) | 3 (6) | 2 (2) | |
| Treatment, n (%) | |||||
| Primary allo-HCT | 747 (17) | 3 (5) | 10 (20) | 36 (27) | <.001 |
| Salvage allo-HCT | 915 (20) | 13 (22) | 8 (16) | 22 (17) | .189 |
| . | CEBPAwt n = 4468 . | CEBPAsmTAD n = 60 . | CEBPAsmbZIP n = 49 . | CEBPAbi n = 131 . | P (adj.) . |
|---|---|---|---|---|---|
| Age, y, median (IQR) | 57 (46-67) | 63 (55-69) | 50 (39-57) | 46 (38-59) | <.001 |
| Sex, n (%) | |||||
| Female | 2170 (49) | 32 (53) | 16 (33) | 70 (53) | .26 |
| Male | 2298 (51) | 28 (47) | 33 (67) | 61 (47) | |
| AML type, n (%) | |||||
| de novo | 3510 (78) | 50 (84) | 47 (96) | 122 (93) | .001 |
| sAML | 630 (14) | 8 (13) | 2(4) | 4 (3) | |
| tAML | 328 (7) | 2 (3) | — | 5 (4) | |
| Laboratory, median (IQR) | |||||
| BM blasts, % | 60 (38-80) | 60 (43.3-72.8) | 65.3 (43.9-80) | 64 (50-87) | .823 |
| CD34-positivity, % | 16 (2-47) | 19.2 (3.8-65) | 45 (19.5-68) | 55.6 (32.9-77) | <.001 |
| WBC, ×109/L | 11.7 (3-45.7) | 13.2 (3.3-51.2) | 35.7 (11.5-93) | 23.7 (9.3-64.7) | <.001 |
| LDH, U/L | 412.9 (272-727) | 412 (291-569) | 491 (344-941) | 445 (292-679) | .99 |
| FAB, n (%) | |||||
| M0 | 223 (5) | — | 1 (2) | — | <.001 |
| M1/M2 | 2040 (46) | 40 (67) | 39 (80) | 101 (77) | |
| M4-M7 | 1535 (34) | 15 (25) | 8 (16) | 19 (15) | |
| Unknown | 670 (15) | 5 (8) | 1 (2) | 10 (8) | |
| Cytogenetics, n (%) | |||||
| Normal karyotype | 1923 (43) | 37 (62) | 34 (72) | 102 (78) | <.001 |
| Aberrant karyotype | 2359 (53) | 23 (38) | 15 (28) | 29 (22) | |
| Unknown | 186 (4) | — | — | — | |
| Favorable risk (MRC) | 353 (8) | 1 (2) | 1 (2) | — | <.001 |
| Intermediate risk (MRC) | 2928 (68) | 54 (90) | 43 (92) | 119 (98) | |
| Adverse risk (MRC) | 1001 (23) | 5 (8) | 3 (6) | 2 (2) | |
| Treatment, n (%) | |||||
| Primary allo-HCT | 747 (17) | 3 (5) | 10 (20) | 36 (27) | <.001 |
| Salvage allo-HCT | 915 (20) | 13 (22) | 8 (16) | 22 (17) | .189 |
Bold P-values indicate statistically significant results.
BM, bone marrow; FAB, French-American-British; LDH, lactate dehydrogenase; MRC, medical research council.